TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01220167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS without water
Description: Single dose of Ondansetron 8 mg (ODFS) administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS without water
Description: Single dose of Ondansetron 8 mg (ODFS) administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS without water
Description: Single dose of Ondansetron 8 mg (ODFS) administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS with water
Description: Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS with water
Description: Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg ODFS with water
Description: Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT (ondansetron 8 mg) without water
Description: Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
Study: NCT05490901

Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise hemodynamic test
Description: Assessment of pulmonary hemodynamics during exercise by right heart catheterization and cardiac function during exercise by a simultaneous transthoracic echocardiography
Study: NCT00530140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular lymphoma, patient-specific, soluble protein idiotype vaccine
Description: 0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
Study: NCT01635205

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paraspinous anesthetic block
Description: Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
Study: NCT01681030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST™
Description: EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Topical hemostat
Description: Equine collagen with Human Fibrinogen and Human Thrombin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
Study: NCT03501875

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CAC Score
Description: Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
Study: NCT01325675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
Study: NCT01635205

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: subcutaneous puncture with no anesthetic effect
Description: Subcutaneous puncture with injection needle (no substance will be injected)
Study: NCT04432948

Intervention type: OTHER
Intervention: PHQ-9 Depression Scale
Description: It involves a 9-question scale that detects depression

Intervention type: OTHER
Intervention: GAD-7 General anxiety disorder scale
Description: It involves a 7-question scale that detects general anxiety disorder

Intervention type: OTHER
Intervention: 38-questions questionnaire
Description: It involves a 38 question questionnaire that aims to detect any association between the Covid-19 pandemic, the psychological impllications and anaesthetic practice
Study: NCT01811043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Dialogue
Study: NCT01077427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Cisplatin + regional hyperthermia
Description: Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3\* and 16, 17\* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3\*, and 16, 17\* of each course~\* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Capecitabine
Description: Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles
Study: NCT02233452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
Study: NCT01220167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT (ondansetron 8 mg) without water
Description: Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zofran ODT (ondansetron 8 mg) without water
Description: Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water
Study: NCT02233452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone plus Ketamine
Description: the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
Study: NCT01789567

Intervention type: DEVICE
Group type: OTHER
Intervention: Engager™ aortic valve
Description: Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
Study: NCT03498859

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapist-supervised training
Description: The intervention is physiotherapist-supervised training once per week during 10 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Home-based training
Description: The intervention is home-based training during 10 weeks
Study: NCT06162962

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Retrospective analysis

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Retrospective analysis

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Retrospective analysis
Study: NCT02071199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1X ACCS (Amnion-derived Cellular Cytokine Solution)
Description: 1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Saline will be applied to the gingival margin daily 5 days per week for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3X ACCS
Description: 0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
Study: NCT06162962

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Retrospective analysis

Intervention type: OTHER
Intervention: Retrospective analysis
Description: Retrospective analysis
Study: NCT01775475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01076153

Intervention type: DRUG
Intervention: Clarithromycin (Klacid® MR)
Description: Klacid MR 500mg (clarithromycin)
Study: NCT03700112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL Virginia Tobacco flavored 5.0% ENDS
Description: Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PMI iQOS Heat sticks
Description: PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
Study: NCT02472288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
Study: NCT02933281

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Escalating dose levels (5 x 10\^3 CFU, 5 x 10\^4 CFU, 5 x 10\^5 CFU, and 5 x 10\^6 CFU

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: BCG 5 x 10\^5 CFU
Study: NCT02148302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harvesting Device (CelluTome©)
Description: Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
Study: NCT03700112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reynolds VUSE Solo ENDS - Original
Description: Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imperial MyBlu ENDS - Original
Description: Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altria MarkTen ENDS - Bold Classic
Description: Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
Study: NCT02382445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anesthesia depth monitor

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol and sevoflurane

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: propofol and sevoflurane
Study: NCT03700112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLV PHIX ENDS - Original Tobacco
Description: MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NJOY Daily EXTRA ENDS - Rich Tobacco
Description: NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altria Marlboro combustible cigarette - Red
Description: Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
Study: NCT03361293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: BrainHQ Computerized cognitive training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive training
Description: BrainHQ Computerized cognitive training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
Study: NCT02341235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game intervention
Description: The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
Study: NCT01392131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oncoxin
Description: 20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
Study: NCT01028417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platinum microcoil
Description: Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
Study: NCT03690583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
Study: NCT00372268

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aeroneb® Pro (Nektar® Company)
Description: The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb® Pro (Nektar® Company)
Description: The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb® Pro (Nektar® Company)
Description: The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aeroneb® Pro (Nektar® Company)
Description: The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
Study: NCT04254224

Intervention type: PROCEDURE
Intervention: colon resection, stoma
Description: oral or intravenous antibiotics treatment with or without percutanous or transrectal or transvaginal drainage
Study: NCT04426318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program Foundations Training
Description: The HMP is a novel, smartphone-based app that provides a series of guided meditation practices on four primary constituents of well-being: Awareness, Connection, Insight, and Purpose. The program is unique in several ways. First, all program elements are introduced with a summary of the scientific evidence supporting its constituent elements (e.g., Awareness and well-being). Second, in addition to standard sitting meditation practices found in many meditation-based behavioral interventions, the HMP offers active practices in which participants can develop the same skills but while embedding practice into activities they already do in their normal daily routine.
Study: NCT03675373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile chat-based instant messages
Description: Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol brief intervention
Description: Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol brief intervention
Description: Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
Study: NCT01135615

Intervention type: DRUG
Group type: OTHER
Intervention: Sevelamer
Description: The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day